KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Operations (2016 - 2025)

Jazz Pharmaceuticals has reported Cash from Operations over the past 16 years, most recently at 362518000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 362518000.0 for Q4 2025, down 9.05% from a year ago — trailing twelve months through Dec 2025 was 1355773000.0 (down 2.88% YoY), and the annual figure for FY2025 was 1355773000.0, down 2.88%.
  • Cash from Operations for Q4 2025 was 362518000.0 at Jazz Pharmaceuticals, down from 474616000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for JAZZ hit a ceiling of 474616000.0 in Q3 2025 and a floor of 41695000.0 in Q2 2021.
  • Median Cash from Operations over the past 5 years was 305115500.0 (2022), compared with a mean of 294708600.0.
  • Biggest five-year swings in Cash from Operations: plummeted 77.16% in 2021 and later skyrocketed 626.79% in 2022.
  • Jazz Pharmaceuticals' Cash from Operations stood at 177755000.0 in 2021, then surged by 92.38% to 341971000.0 in 2022, then plummeted by 51.07% to 167339000.0 in 2023, then skyrocketed by 138.19% to 398580000.0 in 2024, then fell by 9.05% to 362518000.0 in 2025.
  • The last three reported values for Cash from Operations were 362518000.0 (Q4 2025), 474616000.0 (Q3 2025), and 88855000.0 (Q2 2025) per Business Quant data.